9
Active INDs
4
Technology Platforms
600
Employees

Recent News

Athenex to Highlight Oral Paclitaxel Clinical Programs Targeting Various Solid Tumors at the ESMO Congress 2019

Athenex to Present at the 2019 San Antonio Breast Cancer Symposium

Athenex Completes Construction of New API Facility in Chongqing

Athenex Announces Initiation of Phase I Clinical Study in China of KX2-361 Oral by Partner Guangzhou Xiangxue Pharmaceutical

Athenex Announces Appointment of Daniel Lang MD to Lead TCR-T Immunotherapy Operations and Support Corporate Development Strategy

Athenex, Inc. Announces Second Quarter 2019 Financial Results, Positive Phase III Results on Oral Paclitaxel plus Encequidar and Increased Product Sales Guidance

Athenex Announces Oral Paclitaxel and Encequidar had a Significantly Higher Response Rate Over IV Paclitaxel in a Phase III Pivotal Study in Metastatic Breast Cancer

Athenex Provides an Update Regarding the Vasopressin Case

Athenex, Inc. to Report Second Quarter 2019 Earnings Results on August 7, 2019

Other Highlights

Photography by Christopher Galluzzo / Nasdaq, Inc.

Photography by Christopher Galluzzo / Nasdaq, Inc.

On June 14, 2017, Athenex celebrated its initial public offering (IPO) at the Nasdaq MarketSite in Times Square.

Athenex is building a 409,000 square foot manufacturing facility in Dunkirk, NY, with support from New York State.